For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 31,856,252 | |||
| General and administrative | 7,846,379 | |||
| Loss from operations | -39,702,631 | |||
| Interest income | 3,378,545 | |||
| Other income (expense) | 200,471 | |||
| Net loss | -36,123,615 | |||
| Basic EPS | -0.38 | |||
| Diluted EPS | -0.38 | |||
| Basic Average Shares | 95,185,683 | |||
| Diluted Average Shares | 95,185,683 | |||
Context Therapeutics Inc. (CNTX)
Context Therapeutics Inc. (CNTX)